. 2020 Nov 7;37(5):705–711. doi: 10.5114/ada.2020.100481

Table 4.

IL-6 (pg/ml) serum levels in the CONTROL group and in the psoriasis group at baseline and at the 3^rd, 12^th, 24^th, 36^th month of biologic therapy

Study group	Baseline	3^rd month	12^th month	24^th month	36^th month	Control vs. baseline	Repeated measures
Control	6.53 ±2.13
Adalimumab	5.58 ±1.34	3.21 ±0.49	2.65 ±0.53	2.65 ±0.45	2.88 ±0.52	0.6473	0.0003^*
Etanercept	10.12 ±9.76	2.47 ±2.24	4.00 ±3.99	3.00 ±2.34	3.22 ±2.73	0.3455	0.0093^*
Infliximab	20.34 ±30.59	11.20 ±15.69	21.26 ±38.68	16.10 ±29.79	7.32 ±9.77	0.3195	0.0157^*
Ustekinumab	6.26 ±2.87	12.27 ±15.36	4.41 ±2.24	5.31 ±4.42	4.74 ±2.79	0.8587	0.0043^*

Data shown as means ± SEM. ^*Statistically significant findings.